Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22773209 | 0.92 | DRD2 (0.39) | MGLLSMYD3DRD2DRD4DRD3 | |
| SCHEMBL22773249 | 0.89 | KCNH2 (0.42) | SMYD3KCNH2SLC6A3MAPTHTT | |
| SCHEMBL22491371 | 0.79 | NR3C1 (0.44) | MGLLSMYD3KCNH2MAPTHTT | |
| SCHEMBL29734397 | 0.78 | MGLL (0.56) | MGLLMAPT | |
| SCHEMBL22491416 | 0.78 | MGLL (0.56) | MGLLMAPT | |
| SCHEMBL22491384 | 0.78 | MGLL (0.56) | MGLLMAPT | |
| SCHEMBL22491341 | 0.78 | MGLL (0.56) | MGLLMAPT | |
| SCHEMBL29734494 | 0.75 | MGLL (0.53) | MGLL | |
| SCHEMBL29734492 | 0.75 | MGLL (0.53) | MGLL | |
| SCHEMBL22491402 | 0.74 | MGLL (0.54) | MGLLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | claimed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | claimed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | claimed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | claimed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | MGLL 1532/4885SMYD3 1397/4885KCNH2 578/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | MGLL 1532/4885SMYD3 1397/4885KCNH2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.